Terhi Laakso
tervai@utu.fi +358 29 450 2340 +358 50 560 4170 Kiinamyllynkatu 10 Turku |
- Long-term neutralization capacity of vaccine and breakthrough infection induced SARS-CoV-2 specific antibodies against omicron subvariants BA.2, XBB.1.5, and JN.1 (2025)
- Vaccine